HC Wainwright & Co. Reiterates Buy on Aclaris Therapeutics, Maintains $43 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Raghuram Selvaraju has reiterated a 'Buy' rating on Aclaris Therapeutics (NASDAQ:ACRS) and maintained a $43 price target.
October 04, 2023 | 10:22 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Aclaris Therapeutics has received a reiterated 'Buy' rating from HC Wainwright & Co. with a maintained price target of $43.
The reiterated 'Buy' rating and maintained price target by HC Wainwright & Co. indicates a positive outlook for Aclaris Therapeutics. This could potentially attract more investors, driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100